BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RemeGen Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies RemeGen Co.\, Ltd.'s drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06221748-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, Gastric Cancer.\nStudy: DV Comb
 ined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and 
 Gastroesophageal Junction Adenocarcinoma After Progression on First-line T
 herapy\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT04879329)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A S
 tudy of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer
  That Expresses HER2\nEstimated primary completion: 11 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04879329
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined With Toripalimab For First-line Treatment of Uro
 thelial Carcinoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249632-5453@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07249632)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: A Study of Telitacicept in Pati
 ents With Ocular Myasthenia Gravis (OMG)\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07249632
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated 
 Urothelial Cancer Expressing HER2\nEstimated primary completion: 29 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05911295
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456580-5453@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Telitacicept: Phase 3 readout est. (NCT06456580)
DESCRIPTION:Telitacicept\, phase 3\, Generalized Myasthenia Gravis.\nStudy:
  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravi
 s (UPSTREAM MG)\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456580
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462143-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:RC148: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:RC148\, phase 2/3.\nStudy: A Phase Ⅱ/Ⅲ Clinical Trial of RC
 148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorec
 tal Cancer\nEstimated primary completion: 12 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07462143
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06155396-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06155396)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: A Study of RC48-ADC Combin
 ation With Zimberelimab Injection Therapies at Least First-line Platinum-c
 ontaining Standard Therapy Failed With Recurrent or Metastatic Cervical Ca
 ncer\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06155396
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966453-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06966453)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: A Study of Disitamab Vedotin in Adults With HER2 Expressing A
 dvanced Breast Cancer\nEstimated primary completion: 25 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06966453
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874282-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 2 readout est. (NCT07874282)
DESCRIPTION:RC148\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase II 
 Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-
 1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cel
 l Lung Cancer\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07874282
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745740-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT05745740)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Ad
 vanced or Metastasis NSCLC With HER2 Mutation\nEstimated primary completio
 n: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 isitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05745740
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04400695-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT04400695)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of RC48-ADC for the Treatment of Locally Advanced or Me
 tastatic Breast Cancer With Low Expression of HER2\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04400695
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416474-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 3 readout est. (NCT07416474)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RC148 Plu
 s Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemothe
 rapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07416474
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combine
 d With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junct
 ion Adenocarcinoma\nEstimated primary completion: 15 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895355-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:RC148: Phase 2 readout est. (NCT07895355)
DESCRIPTION:RC148\, phase 2.\nStudy: Phase II Clinical Study of RC148 (ABBV
 -1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemo
 therapy) for Unresectable Colorectal Cancer\nEstimated primary completion:
  July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0789535
 5
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404865-5453@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07404865)
DESCRIPTION:Telitacicept\, phase 3\, Sjögren's Disease.\nStudy: Phase 3 St
 udy of Telitacicept in Active Primary Sjögren's Disease\nEstimated primar
 y completion: December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/telitacicept#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07404865
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07936487-5061@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:RC28-E: Phase 3 readout est. (NCT07936487)
DESCRIPTION:RC28-E\, phase 3\, Diabetic Macular Edema.\nStudy: IIIb Trial f
 or RC28-E Injection in Participants With DME and wAMD\nEstimated primary c
 ompletion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rc28-e#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07936487
URL:https://assetmemo.bio/drug/rc28-e#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378242-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06378242)
DESCRIPTION:Disitamab Vedotin\, phase 1/2.\nStudy: To Evaluate the Safety\,
  Efficacy\, and Pharmacokinetics of Intravesical Instiliations of Disitama
 b Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer 
 (NMIBC) That Express HER2\nEstimated primary completion: 15 March 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06378242
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495033-5453@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07495033)
DESCRIPTION:Telitacicept\, phase 3.\nStudy: Phase III Clinical Trial of Tel
 itacicept Injection in the Treatment of Patients With Connective Tissue Di
 sease-related Interstitial Lung Disease\nEstimated primary completion: 31 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telitacicep
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 495033
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315750-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT07315750)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined
  With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Ad
 vanced Gastric or Gastroesophageal Junction Adenocarcinoma.\nEstimated pri
 mary completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07315750
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2454@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Gastric Cancer.\nStudy: A Study o
 f Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated
  primary completion: 28 July 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06157892
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756645-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:RC148: Phase 3 readout est. (NCT07756645)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study t
 o Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembroliz
 umab Combined With Chemotherapy for the First Line Treatment of Locally Ad
 vanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants\nEstima
 ted primary completion: December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07756645
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935369-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:RC148: Phase 2/3 readout est. (NCT07935369)
DESCRIPTION:RC148\, phase 2/3.\nStudy: RC118 Combined With RC148 as First-L
 ine Treatment for Claudin 18.2-Positive\, HER2-Negative Advanced G/GEJ Ade
 nocarcinoma\nEstimated primary completion: 30 April 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07935369
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829549-2698@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:RC148: Phase 3 readout est. (NCT07829549)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phase III
  Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as
  First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without 
 Actionable Genomic Alterations\nEstimated primary completion: April 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07829549
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
